Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CALC 
CalciMedica, Inc. Common Stock (CALC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CALC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $16.25
1 Year Target Price $16.25
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -49.64% | Avg. Invested days 25 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 38.14M USD | Price to earnings Ratio - | 1Y Target Price 16.25 |
Price to earnings Ratio - | 1Y Target Price 16.25 | ||
Volume (30-day avg) 4 | Beta 1.29 | 52 Weeks Range 1.42 - 5.97 | Updated Date 08/29/2025 |
52 Weeks Range 1.42 - 5.97 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.61 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate 7.12 | Actual -0.4 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -77.95% | Return on Equity (TTM) -209.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 28687043 | Price to Sales(TTM) - |
Enterprise Value 28687043 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.26 | Shares Outstanding 13972200 | Shares Floating 5423440 |
Shares Outstanding 13972200 | Shares Floating 5423440 | ||
Percent Insiders 16.76 | Percent Institutions 58.66 |
Upturn AI SWOT
CalciMedica, Inc. Common Stock
Company Overview
History and Background
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for inflammatory and autoimmune diseases with unmet medical needs. Founded in 2006, they are pioneering a new class of therapeutics based on CRAC channel inhibition.
Core Business Areas
- CRAC Channel Inhibitors: CalciMedica focuses on developing CRAC channel inhibitors as a therapeutic approach for various inflammatory and autoimmune diseases. ORAI1-selective CRAC channel inhibitor.
Leadership and Structure
The leadership team includes Rachel Leheny, M.D., Ph.D., as Chief Executive Officer. The company operates with a team focused on research, development, and clinical trials of their therapeutic candidates.
Top Products and Market Share
Key Offerings
- CRISPR (Orai1 Inhibitor): CalciMedica is developing CRISPR, an ORAI1-selective CRAC channel inhibitor, for the treatment of acute pancreatitis with systemic inflammatory response syndrome (SIRS). There is no directly comparable market share data readily available for this specific, unapproved product. Competitors in the broader inflammatory disease market include companies with TNF inhibitors and other immunosuppressants (e.g., ABBV, JNJ).
Market Dynamics
Industry Overview
The biopharmaceutical industry is rapidly growing, with a significant focus on developing novel therapies for inflammatory and autoimmune diseases. Significant unmet needs exist.
Positioning
CalciMedica is positioned as a company pioneering CRAC channel inhibition for treating inflammatory and autoimmune diseases. Their competitive advantage lies in their unique therapeutic approach targeting CRAC channels.
Total Addressable Market (TAM)
The total addressable market (TAM) for inflammatory and autoimmune disease therapeutics is estimated to be billions of dollars annually. CalciMedica is positioned to capture a portion of this market with successful development and commercialization of their product candidates.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (CRAC channel inhibition)
- Clinical-stage pipeline
- Experienced leadership team
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on clinical trial success
- Concentration of pipeline on a single therapeutic target
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to address additional indications
- Positive clinical trial results driving valuation
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- ABBV
- JNJ
- PFE
- NVS
Competitive Landscape
CalciMedica faces competition from established pharmaceutical companies with approved therapies for inflammatory and autoimmune diseases. Its advantage lies in its novel therapeutic approach, but it must demonstrate clinical efficacy and safety to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends can only be provided when access is given to a financial database.
Future Projections: Future projections can only be provided when access is given to a financial database. Analyst projections depend on clinical trial results and regulatory approval timelines.
Recent Initiatives: Recent initiatives include advancing the clinical development of CRAC channel inhibitor.
Summary
CalciMedica is a clinical-stage biopharmaceutical company pioneering CRAC channel inhibition, presenting a novel approach to treating inflammatory and autoimmune diseases. A strength lies in their clinical pipeline, but they have weaknesses in financial resources. Securing partnerships and achieving positive clinical results are important for growth. They face threats from competitors and regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data may be outdated and should be verified with current sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CalciMedica, Inc. Common Stock
Exchange NASDAQ | Headquaters La Jolla, CA, United States | ||
IPO Launch date 2020-09-25 | CEO & Director Dr. A. Rachel Leheny Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://calcimedica.com |
Full time employees 15 | Website https://calcimedica.com | ||
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops Auxora for the treatment of acute ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory indications. The company is based in La Jolla, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.